Peer-reviewed veterinary case report
Phenylpropanolamine (Proin) raises eye pressure and changes tear
By Jung, Sunjun et al.·Published in American journal of veterinary research·2026·Department of Veterinary Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Phenylpropanolamine (Proin) increases intraocular pressure and alters tear production in dogs.
- Species:
- dog
Plain-English summary
A group of healthy Beagle puppies aged 7.5 to 10 months was given a medication called phenylpropanolamine (Proin) to see how it affected their eye pressure and tear production. After taking the medication for four weeks, the puppies showed an increase in eye pressure, which could be a concern for dogs with existing eye problems like glaucoma. Additionally, their tear production decreased during treatment. While these changes weren't severe for most dogs, those with higher initial eye pressure experienced more noticeable fluctuations. It's important for pet owners to discuss the risks of this medication with their veterinarian, especially if their dog has eye issues.
People also search for: dog eye pressure medication · Proin side effects in dogs · Beagle tear production issues
Abstract
OBJECTIVE: To determine the effect of phenylpropanolamine (PPA; Proin) on intraocular pressure (IOP) and Schirmer tear test-I (STT-I) values in dogs. METHODS: Following baseline ophthalmic examinations, including IOP and STT-I measurements, 6 healthy, purpose-bred intact female Beagles aged 7.5 to 10 months were orally administered PPA at 2 mg/kg twice daily over a 4-week period. Intraocular pressure was measured twice weekly at 8:00 am, 12:00 pm, and 4:00 pm. Schirmer tear test-I was measured once weekly. A complete ophthalmic examination was conducted every 2 weeks. Intraocular pressure measurement continued once weekly for a 2-month period following discontinuation of PPA. Descriptive data are presented as mean ± SE of the mean. RESULTS: Compared with pretreatment IOPs (20.8 ± 0.5 mm Hg), values showed a statistically significant increase (23.0 ± 0.3 mm Hg and 21.9 ± 0.3 mm Hg during and after administration, respectively), whereas STT-I values in the right eye showed a statistically significant decrease during PPA administration. Although none of these changes were clinically relevant, dogs with high baseline IOPs exhibited greater fluctuation with elevated IOPs following PPA administration. CONCLUSIONS: PPA administration induced an increase in IOP and exacerbated IOP fluctuation in dogs with high baseline IOP. Phenylpropanolamine should be prescribed with caution in patients with elevated baseline IOP or those predisposed to glaucoma. CLINICAL RELEVANCE: These findings highlight the importance of monitoring IOP in dogs receiving PPA, particularly those with ocular hypertension or a predisposition to glaucoma, to ensure safe clinical use.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41370945/